Attovia Therapeutics, Inc.
- ATTO
- NASDAQ
- Biotechnology
- ATTOBODY Biologics
- IL-31 Therapeutics (Pruritus)
$13.89
Today +1.17%Quote Oct 19, 2026, 08:00 PM UTC
−37.26%over the last month
Max drawdown −38.0%From 1-month high −37.3%3 months −36.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Attovia Therapeutics
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
44
Market value
$634.1M
Quote Oct 19
Floor
$12.35
11.1% below price
Resistance
$14.16
1.9% above price
Price vs analyst targets
Lowest target
$39.00Highest target
$52.00
$39.00Highest target
$52.00
- Price $13.89
- Average target $45.33
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 226% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ATTOPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free